FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890823653> ?p ?o ?g. }

• W2890823653 abstract "e16511 Background: Proxaluatmide is a novel dual MOA androgen receptor (AR) blocker with potent AR antagonist activity and capability to down-regulate AR level. We conducted a first-in-human phase 1 study to investigate safety, tolerability, and pharmacokinetics of GT0918 in patients with advanced CRPC. Methods: All participating patients must be confirmed with advanced CRPC progressed on SoC, PS 0-1, went through 2 periods of time of both single-dose and repeated-dose PK. Patients received GT0918 once orally followed by PK in first 7 days, and then once daily continuously for 28 days for DLT evaluation and repeated-dose PK. PK of drug elimination was done at the end of first cycle (7 days off-treatment). By the end of first 28-day cycle, DLT was evaluated and dose escalation was determined by modified Fibonacci's rule of 3+3 design. If patient tolerated GT0918 well and had no sign of tumor progression, he continued on the study medication thereafter. Results: Ninteen patients were enrolled and 16 patients were treated with GT0918 at five dose levels: 50 mg (n = 2), 100 mg (n = 4), 200 mg (n = 3), 300 mg (n = 3) and 400 mg (n = 4). No DLT was observed. MTD was not reached. GT0918-related adverse events were relatively mild (CTCAE grade 1 or 2), including hypercholesterolemia, peripheral edma, fatigue, flush, constipation and anorexia. PK study showed plasma drug concentrations increased as dose increased from 50mg to 300mg and saturation observed between 300mg and 400mg. Compared single dose (D1) with repeated dose (D35), the elimination half-life (T 1/2 ) were shown 14-35h and 28-51h, respectively. With consideration of overly drug exposure and saturation of oral absorption, 100-400mg were recommended to be the dose range for Phase 2 for further clinical evaluations and dose selection. Clinical activities have been observed in numbers of patients in 100/200/300/400mg dose cohorts. Conclusions: Proxalutamide (GT0918) dosed orally once a day continuously for 12 weeks was generally well tolerated. GT0918 showed promising preliminary anti-tumor activity. Dose range of 100-400mg was recommended for Phase 2 trial and for 24 weeks of treatment." @default.
• W2890823653 created "2018-09-27" @default.
• W2890823653 creator A5011378633 @default.
• W2890823653 creator A5013087679 @default.
• W2890823653 creator A5023418418 @default.
• W2890823653 creator A5037449254 @default.
• W2890823653 creator A5037979928 @default.
• W2890823653 creator A5040133584 @default.
• W2890823653 creator A5040929733 @default.
• W2890823653 creator A5041593666 @default.
• W2890823653 creator A5063652190 @default.
• W2890823653 creator A5072480947 @default.
• W2890823653 creator A5072567913 @default.
• W2890823653 creator A5074003719 @default.
• W2890823653 creator A5088870232 @default.
• W2890823653 creator A5090177552 @default.
• W2890823653 date "2017-05-20" @default.
• W2890823653 modified "2023-09-26" @default.
• W2890823653 title "A first-in-human phase 1 study of proxalutamide (GT0918), a dual MOA androgen receptor blocker in patients with advanced CRPC." @default.
• W2890823653 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e16511" @default.
• W2890823653 hasPublicationYear "2017" @default.
• W2890823653 type Work @default.
• W2890823653 sameAs 2890823653 @default.
• W2890823653 citedByCount "0" @default.
• W2890823653 crossrefType "journal-article" @default.
• W2890823653 hasAuthorship W2890823653A5011378633 @default.
• W2890823653 hasAuthorship W2890823653A5013087679 @default.
• W2890823653 hasAuthorship W2890823653A5023418418 @default.
• W2890823653 hasAuthorship W2890823653A5037449254 @default.
• W2890823653 hasAuthorship W2890823653A5037979928 @default.
• W2890823653 hasAuthorship W2890823653A5040133584 @default.
• W2890823653 hasAuthorship W2890823653A5040929733 @default.
• W2890823653 hasAuthorship W2890823653A5041593666 @default.
• W2890823653 hasAuthorship W2890823653A5063652190 @default.
• W2890823653 hasAuthorship W2890823653A5072480947 @default.
• W2890823653 hasAuthorship W2890823653A5072567913 @default.
• W2890823653 hasAuthorship W2890823653A5074003719 @default.
• W2890823653 hasAuthorship W2890823653A5088870232 @default.
• W2890823653 hasAuthorship W2890823653A5090177552 @default.
• W2890823653 hasConcept C121608353 @default.
• W2890823653 hasConcept C126322002 @default.
• W2890823653 hasConcept C170493617 @default.
• W2890823653 hasConcept C2777911890 @default.
• W2890823653 hasConcept C2780192828 @default.
• W2890823653 hasConcept C61367390 @default.
• W2890823653 hasConcept C71315377 @default.
• W2890823653 hasConcept C71924100 @default.
• W2890823653 hasConcept C98274493 @default.
• W2890823653 hasConceptScore W2890823653C121608353 @default.
• W2890823653 hasConceptScore W2890823653C126322002 @default.
• W2890823653 hasConceptScore W2890823653C170493617 @default.
• W2890823653 hasConceptScore W2890823653C2777911890 @default.
• W2890823653 hasConceptScore W2890823653C2780192828 @default.
• W2890823653 hasConceptScore W2890823653C61367390 @default.
• W2890823653 hasConceptScore W2890823653C71315377 @default.
• W2890823653 hasConceptScore W2890823653C71924100 @default.
• W2890823653 hasConceptScore W2890823653C98274493 @default.
• W2890823653 hasLocation W28908236531 @default.
• W2890823653 hasOpenAccess W2890823653 @default.
• W2890823653 hasPrimaryLocation W28908236531 @default.
• W2890823653 hasRelatedWork W1485660763 @default.
• W2890823653 hasRelatedWork W1530978709 @default.
• W2890823653 hasRelatedWork W1972493003 @default.
• W2890823653 hasRelatedWork W2158604176 @default.
• W2890823653 hasRelatedWork W2317595377 @default.
• W2890823653 hasRelatedWork W2503901337 @default.
• W2890823653 hasRelatedWork W2554518795 @default.
• W2890823653 hasRelatedWork W2561387856 @default.
• W2890823653 hasRelatedWork W2590067686 @default.
• W2890823653 hasRelatedWork W2601568219 @default.
• W2890823653 hasRelatedWork W2886116647 @default.
• W2890823653 hasRelatedWork W2891081513 @default.
• W2890823653 hasRelatedWork W2891532655 @default.
• W2890823653 hasRelatedWork W2914599090 @default.
• W2890823653 hasRelatedWork W2941511463 @default.
• W2890823653 hasRelatedWork W3044351036 @default.
• W2890823653 hasRelatedWork W3048069663 @default.
• W2890823653 hasRelatedWork W3162626122 @default.
• W2890823653 hasRelatedWork W3169114729 @default.
• W2890823653 hasRelatedWork W905145463 @default.
• W2890823653 isParatext "false" @default.
• W2890823653 isRetracted "false" @default.
• W2890823653 magId "2890823653" @default.
• W2890823653 workType "article" @default.